NSCLC MET dysregulations in the form of MET amplification (METamp) have also been shown to act as secondary drivers that can mediate resistance to targeted therapy for other oncogenes such as epidermal growth factor receptor (EGFR) mutations [7,8,16]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.